The latest developments from pharmaceutical and biopharmaceutical companies, both innovator and generic-drug companies, and leading regulatory news.
BioNTech, a Mainz, Germany-based immunotherapy company, which is partnered with Pfizer for the development of a COVID-19 vaccine, has signed a purchase agreement with Novartis to acquire Novartis’ manufacturing facility in Marburg, Germany to...
The latest on manufacturing and potential treatments for COVID-19 with news from Eli Lilly and Company, Amgen, Regeneron, Google, and Vaxart.
Amgen, Lilly in Mfg Pact for COVID-19 Antibody TherapiesAmgen and Eli Lilly and Company have entered into...
Valneva, a Saint-Herblain, France-headquartered vaccine company, has entered into an agreement with the UK government to provide up to 190 million doses of its COVID-19 vaccine candidate, VLA2001, over a five-year period, in a deal worth up to $1.6...
Novavax, a Gaithersburg, Maryland-based clinical-stage vaccine company, has amended a previous agreement with the Serum Institute of India (SII), a Pune, Maharashtra, India-based vaccine manufacturer, under which SII will produce the antigen...
Takeda has opened a new 24,000-square-foot R&D and clinical cell-therapy manufacturing facility at its R&D headquarters in Boston, Massachusetts.
The facility will produce cell therapies for clinical evaluation from discovery through Phase...
Mylan and Pfizer have received final approval from the European Commission (EC) for their proposed combination of Mylan and Upjohn, Pfizer’s off-patent branded and generic established medicines business. The companies had announced the planned...
AstraZeneca reports that clinical trials for its COVID-19 vaccine, AZD1222, have resumed in the UK following confirmation by the UK pharmaceutical regulatory authority, the Medicines Health Regulatory Authority (MHRA), that it was safe to do so...
Merck & Co. and Seattle Genetics, a Bothell, Washington-headquartered biopharmaceutical company, have formed a collaboration, in a deal worth up to $4.2-billion, for Seattle Genetics’ ladiratuzumab vedotin, an investigational antibody drug...
Gilead Sciences has agreed to acquire Immunomedics, a Morris Plains, New Jersey-based clinical-stage biopharmaceutical company focused on antibody-drug conjugates (ADCs), for $21 billion.
Immunomedics’ lead product is Trodelvy (sacituzumab...
Biogen has announced a $250-million, 20-year initiative to eliminate fossil fuels across its operations and collaborate with institutions to advance the science on the health and environmental impacts of climate change. The initiative’s funding...
The US Department of Health and Human Services (HHS) and the US Department of Defense (DoD) released two documents outlining the US government’s strategy to deliver COVID-19 vaccine doses once vaccines are proven effective and safe and are...
A roundup of news from Germany (Bayer, Recursion), India (Mylan), Spain (Grifols, Alkahest), and the US (Merck KGaA, Pfizer, NKMax America).
Germany
Bayer, Recursion in AI Drug-Discovery Pact; Bayer Takes $50-M StakeBayer and Recursion...
AstraZeneca reports that is has temporarily paused its clinical trials for its COVID-19 vaccine, AZD1222, to allow an independent committee to review the safety data of a single event of an unexplained illness that occurred in a Phase III trial in...
The chief executive officers (CEOs) of nine biopharmaceutical companies developing COVID-19 vaccines issued a safety pledge to show united commitment to uphold the integrity of the scientific process as they work toward potential global regulatory...
Takeda Pharmaceutical has agreed to divest a portfolio of select prescription pharmaceutical products to Cheplapharm, a specialty pharmaceutical company headquartered in Greifswald, Germany, for $562 million.
The portfolio to be divested is...
